Supersonic Imagine Announces the Production of its 500th Aixplorer® Ultrasound System in the World
Three years after the market introduction of the first Aixplorer® , SuperSonic Imagine, the innovative ultrasound company, announces the production of its 500th ultrasound system. The unit was shipped to Canon MJ, SuperSonic Imagine’s exclusive distributor in Japan.
Aixplorer® is a unique ultrasound system that provides exceptional image quality and revolutionary UltraFast(TM) Doppler and ShearWave(TM) Elastography for improved tissue characterization.
Worldwide success: Aixplorer is approved in 54 countries
Aixplorer by SuperSonic Imagine is now well-known worldwide.
In the U.S .A. , SuperSonic Imagine has signed a 3 year contract with MAGNET, one of the oldest, largest and most experienced shared service organizations in the country, who serve more than 9,500 hospitals and medical centers. Since 2010, SuperSonic Imagine has also had an exclusive distribution agreement with Hologic, Inc. for breast ultrasound imaging. The Aixplorer system can be found in world renowned locations such as Mayo Clinic (Minnesota), Northwestern University Hospital (Illinois), Baylor (Texas), Yale (Connecticut), Wake Forrest Baptist (North Carolina), and The Massachusetts General Hospital in Boston.
In France , prestigious hospitals and cancer treatment centers such as Grenoble University Hospital, Nice, Lille, Amiens, Cannes, Brest, and AP-HP Georges Pompidou European Hospital and Pitié-Salpetriere, Hospital of Timone in Marseille, the Centers Laccassagne in Nice, Henri Becquerel in Rouen, or the Bergonié Institute in Bordeaux are equipped with Aixplorer.
In Germany, University hospitals of Düsseldorf, Kiel, Greifswald, Aachen, Münster, and Munich Breast Center and Munich Urological Center also use the Aixplorer.
In Russia , SuperSonic Imagine won, in 2010, a bid to equip 26 hospitals with the Aixplorer for the detection and evaluation of hepatic cirrhosis.
SuperSonic Imagine holds the exclusive right, title and interest to international patents and submissions in diagnostic imaging and therapy applications, to exclusively use UltraFast(TM) Doppler and ShearWave(TM) Elastography technologies.
About SuperSonic Imagine (www.supersonicimagine.com )
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic
Imagine is an innovative, international company specializing in
ultrasound medical imaging. The company designs, develops, and markets a
revolutionary ultrasound system, Aixplorer®, with a unique ultrasound
imaging technology, called MultiWave(TM)
Technology. This
technology allows Aixplorer® to be the only ultrasound system that
images two types of waves to better characterize tissue; an ultrasound
wave to ensure impeccable image quality and a shear wave, ShearWave(TM)
Elastography, to compute and display true tissue stiffness in real time
by acquiring images nearly 200 times faster than conventional systems.
In
2009, SuperSonic Imagine was granted 510(k) clearance by the Food and
Drug Administration in the United States and CE mark in Europe for the
marketing of Aixplorer®.
Distribution agreements have been signed
with prestigious companies such as Hologic (Nasdaq : HOLX) for the
breast market in the U.S.A. and Canon (NYSE : CAJ) for Japan. SuperSonic
Imagine’s distribution network has now more than 30 partners worldwide.
Contact:
SuperSonic Imagine
Michele Debain
Global Marketing
Director
michele.debain@supersonicimagine.fr
+33
(0)4 42 99 24 32
or
H&B Communication
Media
Relations
Florence Portejoie
f.portejoie@hbcommunication.fr
+33
(0)1 58 18 32 58 / +33 (0)6 88 84 81 74
or
Anne Hardy
a.hardy@hbcommunication.fr
+33
(0)1 58 18 32 51 / +33 (0)6 13 56 23 96
or
New
Cap.
Investor
Relations
Pierre Laurent / Florent Alba
supersonic@newcap.fr
+33
(0)1 44 71 98 55
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 12:50:00 CEST | Press release
Revenue of $8.49 billion decreased 3% year on year GAAP EPS of $0.58 decreased 22% year on year EPS, excluding charges and credits, of $0.72 decreased 4% year on year Net income attributable to SLB of $797 million decreased 25% year on year Adjusted EBITDA of $2.02 billion decreased 2% year on year Cash flow from operations of $660 million increased $333 million year on year Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9%
Corona, The World’s Most Valuable Beer Brand1, Announces Its 100-Year Anniversary with Global Celebration25.4.2025 10:00:00 CEST | Press release
Brand Invites The World to Join the Celebration with Experiences at the Most Epic Beaches on EarthGlobal “Corona 100” Platform Launches with a Legendary Concert at Copacabana Beach, Featuring One of the World’s Top Musical Artists with Millions in Attendance Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive l
Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 09:28:00 CEST | Press release
Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom